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Bilirubin is generated from the breakdown of heme by heme oxygenase and the reduction
of biliverdin by the enzyme biliverdin reductase. Several large population studies have
reported a signiﬁcant inverse correlation between plasma bilirubin levels and the inci-
dence of cardiovascular disease. Protection from cardiovascular disease is also observed in
patients with Gilbert’s syndrome which is a disease characterized by mutations in hepatic
UGT1A1, the enzyme responsible for the conjugation of bilirubin into the bile. Despite the
strong correlation between plasma bilirubin levels and the protection from cardiovascu-
lar disease, the mechanism by which increases in plasma bilirubin acts to protect against
cardiovascular disease is unknown. Since the chronic antihypertensive actions of bilirubin
are likely due to its renal actions, the effects of moderate increases in plasma bilirubin on
renal hemodynamics as well as bilirubin’s potential effects on renal tubule function will be
discussed in this review.Mechanisms of action as well as the potential for antihypertensive
therapies targeting moderate increases in plasma bilirubin levels will also be highlighted.
Keywords: biliverdin, heme oxygenase, biliverdin reductase, carbon monoxide, UGT1A1, liver, glomerular filtration
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INTRODUCTION
Bilirubin is derived in the plasma from the breakdown of red
blood cells in the spleen. In the spleen, heme oxygenase (HO)
enzymes catabolize heme released from the breakdown of red
blood cells to carbon monoxide (CO) and biliverdin. Biliverdin
is then reduced to bilirubin by the enzyme biliverdin reductase
(BVR) and released into the blood stream. In the blood,most of the
bilirubin is bound to albumin (δ bilirubin) where it travels to the
liver and is conjugated by hepatic UDP-glucuronosyltransferase
(UGT1A1) enzymes. Most of the conjugated bilirubin then exits
the liver through the biliary ducts into the bile where it is elimi-
nated through the digestive system. Gilbert’s syndrome is a disease
characterized by elevations in the levels of unconjugated biliru-
bin in the plasma due to mutations in hepatic UGT1A1 which
decrease conjugation of bilirubin in the liver. Levels of uncon-
jugated bilirubin in the plasma can also be increased by drugs
which compete with bilirubin for conjugation byUGT1A1. Analy-
sis of patients in the Framingham heart study concluded that
mutations in UGT1A1 which resulted in moderate increases in
plasma bilirubin (twofold) were associated with a decrease risk
for the development of cardiovascular disease (Lin et al., 2006).
This is in agreement with previous human population studies
which found that moderated increases in plasma bilirubin were
protective against atherosclerosis, coronary heart disease, meta-
bolic syndrome, diabetic nephropathy, and end stage renal disease
(Hopkins et al., 1996; Novotny and Vitek, 2003; Chin et al., 2009a;
Han et al., 2010; Wu et al., 2011).
It is well established that the kidney’s play a central role the
regulation of arterial pressure. Thus, the chronic antihypertensive
actions of bilirubin are likely due to its renal actions. As men-
tioned above, bilirubin is derived from the breakdown of heme
by HO enzymes. Our knowledge of the effects of bilirubin in the
kidney is mainly derived from studies in which the levels of HO
enzymes have been altered. However, the results obtained from
these studies are complicated by the fact that CO and bilirubin
are generated in equimolar amounts by HO enzymes. This makes
it impossible to separate out the contribution of each metabolite
to any observed response to alterations in HO activity. Given this
fact, we will mainly focus this review on the effects of increases
in plasma bilirubin levels on the regulation of renal vascular and
tubular function as well as the effects of plasma bilirubin on blood
pressure. Studies utilizing alterations of HO enzymes will be dis-
cussed in areas in which data from models of hyperbilirubinemia
are not available and which point to a potential role for bilirubin.
BILIRUBIN AND THE REGULATION OF RENAL
HEMODYNAMICS
Alterations in renal hemodynamics underlie the development
and maintenance of hypertension in several forms including
angiotensin II (Ang II) dependent hypertension (Granger and
Schnackenberg, 2000). Marked elevations in Ang II levels as
observed with models of chronic Ang II infusion decrease
glomerular ﬁltration rate (GFR) due to effects on the afferent
arteriole. TheGunn rat, a rodentmodel of severe (<20 fold) hyper-
bilirubinemia due to loss of hepaticUGT1A1, exhibits a signiﬁcant
50% decrease in the blood pressure response to Ang II infusion.
The Gunn rat also does not exhibit a signiﬁcant decline in GFR in
response to chronic, 4 week infusion Ang II infusion as compared
to control rats (Pﬂueger et al., 2005). In a mouse model of moder-
ate hyperbilirubinemia due to blockade of hepatic UGT1A1 with
either indinavir, an antiretroviral protease inhibitor, or speciﬁc
antisense morpholino oligonucleotides, chronic Ang II infusion
did not result in a decrease in GFR (Figure 1A; Vera and Stec,
2010). Moderate hyperbilirubinemia also preserves renal blood
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FIGURE 1 | (A) Effects of moderate hyperbilirubinemia with indinavir or
UGT1A1 antisense morpholino (UGT1A1 A.S.) on glomerular ﬁltration
rate (GFR) in Ang II infused mice. Ang II infusion resulted in a
signiﬁcant decrease in GFR which was normalized by moderate
hyperbilirubinemia. (B) Effect of moderate hyperbilirubinemia with
indinavir on renal blood ﬂow. Ang II infusion resulted in a signiﬁcant
decline in renal blood ﬂow which was normalized by moderate
hyperbilirubinemia. (C) Effect of moderate hyperbilirubinemia on renal
vascular resistance. Renal vascular resistance was signiﬁcantly
increased by Ang II infusion and was normalized by moderate
hyperbilirubinemia. *=P <0.05 as compared to control. Figure
modiﬁed from Vera and Stec (2010).
ﬂow and normalizes renal vascular resistance in Ang II treated
mice (Figures 1B,C; Vera and Stec, 2010).
Renal afferent arteriole regulation of GFR is accomplished
by two major mechanisms; the myogenic response and tubu-
loglomerular feedback (TGF). The myogenic response is an
endogenous response of blood vessels to constrict when stretched
by increases in translumenal pressure. The myogenic constriction
of the afferent arteriole is believed to help protect the glomeru-
lus from increases in perfusion pressure (Bidani et al., 2009). The
role of bilirubin in modifying myogenic vasoconstriction of the
afferent arteriole has not been investigated. TGF is the second
mechanism by which vascular tone of the afferent arteriole is reg-
ulated. TGF response utilizes sodiumdelivery tomacula densa cells
of the kidney in order to regulate the tone of the afferent arteriole.
The macula densa cells convey a signal to the afferent arteriole to
constrict in response to increases in sodium delivery to the mac-
ula densa (signal of increase in GFR) and to dilate in response
to decreases in sodium delivery to the macula densa (signal of
decreased GFR). Recent studies have demonstrated an important
role for bilirubin (via conversion from biliverdin) in protecting
against excessive TGFmediated constriction of the afferent arteri-
ole (Ren et al., 2008;Wang et al., 2011). The mechanism by which
bilirubin can protect against TGFmediated vasoconstriction is not
known. It is not clear if moderate increases in plasma bilirubin can
have similar effects on TGFmediated vasoconstriction or whether
this response is dependent on HO generated bilirubin in the mac-
ula densa cells or in the vascular smoothmuscle cells of the afferent
arteriole.
Current evidence suggests that increases in bilirubin (via con-
version from biliverdin) protect against excessive TGF mediated
vasoconstriction and can attenuate constriction to high levels
of vasoconstrictors such as Ang II; however, the mechanism by
which bilirubin can maintain vascular tone is not fully under-
stood. Bilirubin is one of the most potent antioxidants in the
body (Stocker et al., 1987; Stocker and Peterhans, 1989; Bulmer
et al., 2008). Given that vasoconstrictors such as Ang II can stimu-
late superoxide anion production in the vasculature, one potential
mechanism for the protective role of moderate hyperbilirubine-
mia in the renal vasculature is quenching of reactive oxygen species
(ROS) such as superoxide (Griendling et al., 1994; Rajagopalan
et al., 1996; Hanna et al., 2002). This hypothesis is supported by
the observation that Ang II mediated superoxide production is
signiﬁcantly attenuated in aortic ring segments from moderately
hyperbilirubinemic mice (Figure 2A; Vera et al., 2009). Bilirubin
can directly scavenge superoxide but also reduces superoxide pro-
duction via direct inhibition of NAD(P)H oxidases in the vascula-
ture (Lanone et al., 2005). The reduction of superoxide production
in the vasculature by bilirubin is associated with the increase in
the bioavailability of nitric oxide as reﬂected in the nitrate/nitrite
levels in the plasma of chronically infused Ang II hypertensive
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mice made moderately hyperbilirubinemic (Figures 2B and 3;
Vera et al., 2009). Nitric oxide (NO) can react with superoxide to
produce peroxynitrite which is a potent oxidant (Figure 3). It is
possible that moderate increases in plasma bilirubin are able to
preserve renal blood ﬂow and maintain GFR in Ang II-dependent
hypertension through increases in NO; however, the importance
of increased NO to this response remains to be speciﬁcally tested.
Bilirubin may also preserve renal blood ﬂow and GFR through
mechanisms independent of ROSproduction. For example, biliru-
bin can attenuate Ang II mediated increase in preproendothelin
gene transcription in endothelial cells (unpublished observation).
Several studies have demonstrated an important role for endothe-
lin signaling through the endothelin A (ETA) receptor in Ang
II-dependent hypertension (d’Uscio et al., 1997; Rajagopalan et al.,
1997; Ballew and Fink, 2001). Thus, attenuation of Ang II medi-
ated endothelin signaling could contribute to the preservation
of renal blood ﬂow and GFR by moderate hyperbilirubinemia.
Bilirubin may also have effects on calcium handling in vascular
smooth muscle cells through interactions with calcium channels
or the intracellular storing and release of calcium (Figure 3). The
effects of bilirubin on endothelin production and calcium han-
dling need to be further explored to determine the importance of
FIGURE 2 | (A) Moderate hyperbilirubinemia decrease Ang II-dependent
superoxide production in aortic tissue. Superoxide levels were determined
using dihydroethidium (DHE) staining of aortic tissue segments (upper panel).
Ang II treatment resulted in a signiﬁcant increase in aortic superoxide
production which was normalized by moderate hyperbilirubinemia. (B)
Moderate hyperbilirubinemia increases plasma NO levels in Ang II infused
mice. *=P <0.05 vs. Control, † =P <0.05 vs. Ang II. Figure modiﬁed from
Vera et al. (2009).
FIGURE 3 | Schematic of vascular actions of bilirubin. Ang II acts on
the NADPH oxidase to increase superoxide production. Superoxide can
then react with nitric oxide (NO) to form peroxynitrite which inhibits
vasodilatation. Ang II can also stimulate the expression of
preproendothelin (preproET) which is a vasoconstrictor. Bilirubin can
directly scavenge superoxide as well as block NADPH oxidase to
increase the bioavailability of NO and promote vasodilatation. Bilirubin
can also inhibit Ang II mediated increases in preproET and may also block
intracellular calcium through membrane and intracellular calcium
channels.
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these potential mechanisms which protect the renal vasculature
from excessive constriction in Ang II-dependent hypertension.
BILIRUBIN AND THE REGULATION OF RENAL TUBULE
FUNCTION
Very little is currently known about the role of bilirubin in the
regulation of renal tubule function. Sodium and water homeosta-
sis in models of elevated plasma bilirubin such as the Gunn rat
or the moderately hyperbilirubinemic mouse has not been evalu-
ated. The effect that increased renal bilirubin via direct infusion
into the kidney has on sodium excretion is not known. Likewise,
the effect of blockade of bilirubin production on sodium excretion
is also unknown. Several studies in rodents have demonstrated that
induction of renal HO increases sodium andwater excretion while
inhibition of renal HOpromotes sodium reabsorption (Rodriguez
et al., 2003; Li et al., 2007; Jackson et al., 2011). However, the spe-
ciﬁc role of bilirubin in this response is not known. Studies in
cultured renal thick ascending loop of Henle (TALH) cells have
demonstrated that blockade of bilirubin production by targeting
BVR results in increased Ang II mediated superoxide production
and sodiumreabsorption (Figure 4;Young et al., 2009). Thiswould
suggest a potential role for endogenous cellular bilirubin produc-
tion in the regulation oxidative stress and sodium reabsorption in
the TALH.
Bilirubin may affect tubular function through similar mech-
anism as proposed in the renal vasculature (Figure 3). Several
studies have reported an important role for superoxide in stimu-
lating sodium reabsorption in the TALH (Ortiz andGarvin, 2002a;
Juncos and Garvin, 2005). Superoxide can also quench the levels
of nitric oxide to further increase sodium reabsorption in this
nephron segment (Ortiz and Garvin, 2002b). Thus, decreases in
bilirubin production via targeting of biliverdin reductase could
increase sodium reabsorption in the TALH via increased super-
oxide production. Whether decreases in BVR activity could result
in similar increases in sodium reabsorption in the TALH in vitro
is not known. The importance of cellular bilirubin generation to
the natriuresis exhibited with induction of HO-1 in the kidney is
also an area which is unclear. The role of cellular bilirubin gen-
eration will require the development of new experimental models
in which the activity of BVR is reduced genetically either through
chronic knockdown with siRNAs in vivo or the creation of speciﬁc
knockout mice or rats.
BILIRUBIN AND THE REGULATION OF BLOOD PRESSURE
The blood pressure lowering actions of systemic HO-1 induction
have been demonstrated in several rodent models of experimental
hypertension (Sacerdoti et al., 1989; Sabaawy et al., 2001; Botros
et al., 2005; Vera et al., 2007; George et al., 2011). Additional stud-
ies have also revealed that alterations in renal heme oxygenase
activity alone can have profound effects on the development of
hypertension (Li et al., 2007; Vera et al., 2008). While the effects
of alterations of HO activity on blood pressure have been estab-
lished, the speciﬁc role for bilirubin generation in this response
has remained elusive. As mentioned above, it is impossible to sep-
arate the generation of bilirubin from that of CO by HO enzymes
so the relative importance of one vs. the other metabolite in the
actions of HOon blood pressure remains unresolved. Several large
scale human population studies have demonstrated an inverse
relationship between plasma bilirubin levels and the incidence of
hypertension (Chin et al., 2009b). As stated above, alterations in
plasma bilirubin levels are also associated with other cardiovascu-
lar risk factors such as atherosclerosis, diabetic nephropathy, and
renal disease all of which could contribute to the development of
hypertension.
FIGURE 4 | (A) RepresentativeWestern blot of protein lysates from
mouse thick ascending loop of Henle (TALH) cells treated with biliverdin
reductase (BVR) or non-targeting (NT) siRNAs. Treatment with 50 or
100 nM BVR siRNA resulted in signiﬁcant decrease in BVR protein. (B)
Top panel – representative images of dihydroethidium (DHE) staining of
Ang II treatedTALH cells receiving BVR siRNA. (B) Bottom
panel – treatment with 50 or 100 nM BVR siRNA resulted in signiﬁcant
increase in DHE staining. (C) Effect of BVR siRNA treatment on
ouabain-sensitive sodium transport in cultured mouseTALH cells. BVR
siRNA signiﬁcantly increase Ang II-mediated sodium transport. *P <0.05
as compared control. †P <0.05 vs. Ang II. Figure modiﬁed fromYoung
et al. (2009).
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Although it is difﬁcult to determine the speciﬁc role of bilirubin
in the blood pressure response to alterations inHO activity, several
studies have investigated the speciﬁc role of plasma bilirubin lev-
els in the development of hypertension using experimental animal
models in which confounding factors such as atherosclerosis, dia-
betes, and renal injury can be carefully controlled. As mentioned
above, the Gunn rat is a model of severe hyperbilirubinemia char-
acterized by very high levels of plasma bilirubin resulting from
decreased hepatic conjugation due to loss of the UGT1A1 gene
(van et al., 1968; van der Wegen et al., 2006). The Gunn rat has
been demonstrated to be resistant to the development of both Ang
II and deoxycorticosterone acetate (DOCA)-salt dependent hyper-
tension (Pﬂueger et al., 2005; Nath et al., 2007). The resistance
to the development of hypertension in the Gunn rat was associ-
ated with preservation of NO dependent vasorelaxation which is
altered in both of these forms of hypertension. Both of these forms
of hypertension are also characterized by increases in superoxide
anion production which is signiﬁcantly attenuated in the Gunn
rat. The results obtained in the Gunn rat clearly demonstrate the
difﬁculty in obtaining a hypertensive response to known pressors;
however, the level of bilirubin in the plasma of these rats is sig-
niﬁcantly higher than those reported to be beneﬁcial in humans
(Hopkins et al., 1996; Lin et al., 2006).
In order to determine if physiologic increases in bilirubin
(∼twofold) could have similar effects on the development of
hypertension, our lab created a mouse model of moderate hyper-
bilirubinemia achieved through targeting of hepatic UGT1A1
either with a drug which competes with bilirubin for conju-
gation (indinavir) or antisense oligonucleotides directed against
UGT1A1. We were able to ﬁnd concentrations of these agents
which resulted in two to threefold increases in the levels of
plasma unconjugated bilirubin (Figure 5A) which are in con-
trast with the greater than 20 fold elevations in unconjugated
observed in the Gunn rat (van der Wegen et al., 2006). Using
this mouse model, we demonstrated that moderate hyperbiliru-
binemia achieved with indinavir prevented the development of
Ang II mediated hypertension (Figure 5B; Vera et al., 2009). Sim-
ilar effects on the development of Ang II hypertension were also
observed in mice which received direct intravenous infusion of
bilirubin which increased the levels of unconjugated bilirubin
to levels observed in indinavir treated mice (Vera et al., 2009).
As mentioned above, moderate hyperbilirubinemia in this mouse
model was also associated with increases in renal blood ﬂow and
GFR as well as decreases in renal vascular resistance and vascu-
lar superoxide production. These results indicate that selective
targeting of hepatic UGT1A1 to increase plasma unconjugated
bilirubin levels by two to threefoldmay be a novel antihypertensive
approach. In another study, intraperitoneal injection of bilirubin
was found to signiﬁcantly decrease Ang II mediated proteinuria
by 60% while having no signiﬁcant effect on Ang II-dependent
hypertension (LeBlanc et al., 2010). The results of this study sug-
gest that alterations in bilirubin may have beneﬁcial effects on the
kidney independent of changes in blood pressure. However, since
no measurements of plasma or renal bilirubin levels were made
in the treated animals; it is difﬁcult to determine whether the
bilirubin treatment protocol was sufﬁcient to elevate the levels of
unconjugated bilirubin in the plasma enough to lower blood pres-
sure in this model. Nonetheless, this study indicates that bilirubin
may have renoprotective effects in the absence of any changes in
blood pressure.
FUTURE DIRECTIONS AND PERSPECTIVES
Bilirubin either derived intracellularly by generation through
actions of HO or in the plasma regulated by the activity of hepatic
UGT1A1 has been demonstrated to play an important role in
the regulation of blood pressure as well as renal vascular and
tubular function. The challenge in the future is to determine the
mechanism by which the levels of bilirubin in both the cell and
plasma regulate renal vascular and tubular function in the hopes
of creating new targets for therapies. The understanding of cellular
bilirubin generation in the regulation of renal function will rely
on targeting BVR in the kidney either through siRNA mediated
FIGURE 5 | (A) Effect of indinavir or UGT1A1 antisense morpholino
oligonucleotides on plasma unconjugated bilirubin levels in Ang II treated
mice. (B) Effect of moderate hyperbilirubinemia with indinavir treatment
on blood pressure in Ang II infused mice. Mice were made moderately
hyperbilirubinemic by treatment with Indinavir (500mg/kg/day, oral gavage)
starting 3 days before the implantation of minipumps that delivered Ang II
at 1μg/kg/min and continuing throughout the 12 day infusion. Blood
pressure was measured in conscious freely moving mice by ﬂuid ﬁlled
catheters. Ang II infusion increased blood pressure and this increase was
signiﬁcantly attenuated by moderate hyperbilirubinemia. *P <0.05 as
compared control. †P <0.05 vs. Ang II. Figure modiﬁed from Vera et al.
(2009).
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viral approaches or the creation of genetically modiﬁed mice or
rats. Interestingly, a recent human population study correlated a
loss of function mutation in the BVR-A gene with increases in
blood pressure suggesting a potential role for this enzyme in the
regulation of blood pressure (Lin et al., 2011).
The manipulation of plasma levels of bilirubin is an area which
could be further explored as a potential therapeutic approach for
the treatment of hypertension. Targeting the conjugation of biliru-
bin in the liver via UGT1A1 has the potential to be onemechanism
to increase plasma bilirubin levels; however, given the important
role of UGT1A1 in the elimination of drugs from the body other
potential targets in the handling of bilirubin by the liver may need
to be developed. For example,modiﬁcation of proteins responsible
for the transport of bilirubin into and out of hepatocytes may be
another potential target to increase plasma levels of unconjugated
bilirubin for therapeutic purposes. Before targeting of hepatic
bilirubinmetabolism canbe considered for a therapeutic approach
to lower blood pressure and improve renal vascular function, the
mechanism by which increases in plasma bilirubin levels act to
lower blood pressure and improve renal vascular function need to
be identiﬁed. Determination of these mechanisms may take sev-
eral years to develop. It is possible that bilirubin may act as more
than just an antioxidant to elicit its effects on renal hemodynam-
ics and blood pressure. This possibility also needs to be further
tested before targeting of hepatic bilirubin metabolism can move
forward as a potential therapeutic option for hypertension. What
is clear is that bilirubin has moved beyond a simple component of
the plasma responsible for jaundice, to a complex molecule with
several beneﬁcial properties that could be exploited for treatment
of hypertension and renal disease.
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